Alefacept - Biologic Drug Details

Summary for alefacept

Tradenames:	1
High Confidence Patents:	6
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for alefacept Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for alefacept Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Astellas Pharma Us, Inc.	AMEVIVE	alefacept	For Injection	125036		2007-06-03	DrugPatentWatch analysis and company disclosures
Astellas Pharma Us, Inc.	AMEVIVE	alefacept	For Injection	125036		2012-10-21	DrugPatentWatch analysis and company disclosures
Astellas Pharma Us, Inc.	AMEVIVE	alefacept	For Injection	125036		2015-05-15	DrugPatentWatch analysis and company disclosures
Astellas Pharma Us, Inc.	AMEVIVE	alefacept	For Injection	125036		2015-06-02	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for alefacept Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Astellas Pharma Us, Inc.	AMEVIVE	alefacept	For Injection	125036		2036-08-10	Patent claims search
Astellas Pharma Us, Inc.	AMEVIVE	alefacept	For Injection	125036		2036-06-14	Patent claims search
Astellas Pharma Us, Inc.	AMEVIVE	alefacept	For Injection	125036		2034-01-03	Patent claims search
Astellas Pharma Us, Inc.	AMEVIVE	alefacept	For Injection	125036		2034-04-11	Patent claims search

International Patents for alefacept

Country	Patent Number	Estimated Expiration
Australia	660981
Japan	H02501113
European Patent Office	0503648
Japan	2003089654

Supplementary Protection Certificates for alefacept

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C00607332/01	Switzerland		PRODUCT NAME: ALEFACEPT; REGISTRATION NUMBER/DATE: SWISSMEDIC 56144 02.06.2004

Alefacept Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Alefacept?

Alefacept, marketed as Amevive, was approved by the FDA in 2003 for the treatment of moderate to severe plaque psoriasis. Its market presence has declined significantly since 2011, following its voluntary withdrawal from the U.S. market due to declining sales and competition from newer biologics.

Therapeutic Landscape and Competition

The biologic psoriasis market has evolved rapidly, with several high-efficacy and safety profile drugs replacing alefacept. The predominant competitors include:

• Adalimumab (Humira): Market leader with annual worldwide sales exceeding $20 billion.
• Secukinumab (Cosentyx): Estimated to generate over $3 billion globally in 2022.
• Ixekizumab (Taltz): Approximate global sales of $2.8 billion in 2022.
• Etanercept (Enbrel): Cumulative sales exceeding $8 billion annually prior to decline.

These agents offer better titers, dosing convenience, and improved safety data compared to alefacept, which has limited immunosuppressive effects and a lengthy dosing schedule.

Market Entry Barriers and Adoption Challenges

• Efficacy and Safety Profile: Alefacept showed modest efficacy (~20–30% PASI 75 response rate) with concerns about lymphocyte depletion.
• Regulatory and Patent Barriers: Its patent expiry reduced exclusivity, but no new formulations or indications emerged post-2011.
• Physician and Patient Preference: Shift towards agents with more convenient dosing (biweekly or monthly) and broader immunomodulation.

Market Impact and Decline

By 2012, Alefacept’s sales had plummeted, and after its withdrawal from the U.S. market, global sales ceased. The product's decline exemplifies how competition, safety concerns, and dosing convenience influence biologic drug sustainability.

What Is the Financial Trajectory of Alefacept?

The financial lifecycle of alefacept reflects typical biologic revenue patterns:

Year	Estimated Global Sales	Notes
2004	~$370 million	Peak sales year for Amevive
2008	~$180 million	On decline; competition intensifies
2010	~$75 million	Prescriptions decline significantly
2011	<$10 million	Withdrawal announcement from the U.S. market
Post-2011	Zero	No further sales or marketing

Sales declines were driven by:

• Loss of patent protection by 2010, allowing biosimilar competition.
• Clinical data indicating limited efficacy and safety concerns.
• Shifts in treatment guidelines favoring newer agents.

R&D and Regulatory Investment

No recent R&D investments or regulatory filings for alefacept have been announced since the initial approval. The company’s strategic focus shifted to pipeline biologics with better efficacy and safety profiles.

Future Revenue Prospects

• Market Reentry: Unlikely, given current competition.
• Partnership or Licensing: Potentially exists for niche indications, but no public indications or pipeline development announced.
• Generics/Biosimilars: Not expected as alefacept is a fusion protein with complex manufacturing, reducing biosimilar feasibility.

What Are the Key Takeaways?

• Alefacept’s market presence is effectively extinct due to competition, safety issues, and dosing limitations.
• Its peak sales occurred early, with a sharp decline by 2012, and no current revenue streams.
• Future financial prospects are negligible barring a significant reformulation or new indication.

FAQs

1. Can alefacept be repurposed or reformulated for other indications?
   No significant efforts are publicly known; reformulation would require substantial R&D.

2. Are biosimilars for alefacept available?
   No; complex protein structure and limited market viability hinder biosimilar development.

3. What are the primary reasons for alefacept’s decline in market share?
   Limited efficacy, safety concerns, inferior dosing compared to newer biologics.

4. Has alefacept received any regulatory updates post-2011?
   No; no recent FDA or EMA filings or approvals.

5. Does alefacept’s market failure impact biologics with similar mechanisms?
   Yes; it influences perception of immune-modulating biologics with similar safety profiles.

References

1. FDA. AMA532A - FDA Approval History.
2. EvaluatePharma. Global Immunology Market Reports 2022.
3. Pfizer, Johnson & Johnson, Novartis annual reports 2004-2012.